These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19554862)

  • 21. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand.
    Raftery JP
    Med J Aust; 2008 Jan; 188(1):26-8. PubMed ID: 18205559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organ Tech Rep Ser; 2008; (948):1-138. PubMed ID: 18557474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Could conditional release of new drugs provide the information required to study drug effectiveness? - A discussion paper.
    Rawson NS; West R; Appel WC
    Can J Clin Pharmacol; 2000; 7(4):185-90. PubMed ID: 11118964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanocarriers.
    Torchilin VP
    Pharm Res; 2007 Dec; 24(12):2333-4. PubMed ID: 17934800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of PBAC submissions and outcomes for medicines (2010-2018).
    Lybrand S; Wonder M
    Int J Technol Assess Health Care; 2020 Jun; 36(3):224-231. PubMed ID: 32524923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fabrication of solid nanoparticles for drug delivery.
    Arayne MS; Sultana N; Noor-Us-Sabah
    Pak J Pharm Sci; 2007 Jul; 20(3):251-9. PubMed ID: 17545113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Australian funding debate on quadrivalent HPV vaccine: a case study for the national pharmaceutical policy.
    Roughead EE; Gilbert AL; Vitry AI
    Health Policy; 2008 Dec; 88(2-3):250-7. PubMed ID: 18468714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring policy-makers' perspectives on disinvestment from ineffective healthcare practices.
    Elshaug AG; Hiller JE; Moss JR
    Int J Technol Assess Health Care; 2008; 24(1):1-9. PubMed ID: 18218163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Policy challenges of nanomedicine for Australia's PBS.
    Faunce TA
    Aust Health Rev; 2009 May; 33(2):258-67. PubMed ID: 19563314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Striving for quality use of medicines: how effective is Australia's ban on direct-to-consumer prescription medicine advertising?
    Brown S
    J Law Med; 2009 Feb; 16(4):666-83. PubMed ID: 19297873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
    Lexchin J
    Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanotherapeutics: new challenges for safety and cost-effectiveness regulation in Australia.
    Faunce TA
    Med J Aust; 2007 Feb; 186(4):189-91. PubMed ID: 17309421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors affecting toxicity and efficacy of polymeric nanomedicines.
    Igarashi E
    Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How Data Packages Lacking Phase III Pivotal Trial Data Can Support Regulatory Approval and Reimbursement for Oncologics in Australia.
    Macaulay R; Siddiqui MK; Stoddart S
    Value Health Reg Issues; 2015 May; 6():143-149. PubMed ID: 29698188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia.
    Gordois A; Nobes M; Toohey M; Russ G
    Clin Transplant; 2006; 20(4):526-36. PubMed ID: 16842533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Particle engineering techniques for inhaled biopharmaceuticals.
    Shoyele SA; Cawthorne S
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1009-29. PubMed ID: 17005293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The weakest link: demonstrating the inconsistency of "appropriate levels of protection" in Australia-Salmon.
    Atik J
    Risk Anal; 2004 Apr; 24(2):483-90. PubMed ID: 15078319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia.
    Karikios DJ; Chim L; Martin A; Nagrial A; Howard K; Salkeld G; Stockler MR
    Intern Med J; 2017 Apr; 47(4):400-407. PubMed ID: 27928875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organ Tech Rep Ser; 1999; 885():i-vi, 1-156. PubMed ID: 10352573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.